ACE and heart failure: Compared with the gold standard angiotensin-converting enzyme inhibitor (enalapril) an angiotensin receptor-neprilysin inhibitor (sacubitril/valsartan) not only decreases the risk of cardiovascular death or heart failure hospitalization but also improves symptoms in patients with chronic heart failure with reduced ejection fraction (35).